{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:10:31Z","timestamp":1789765831140,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.virusres.2019.197677","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T11:23:54Z","timestamp":1564572234000},"page":"197677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly"],"prefix":"10.1016","volume":"271","author":[{"given":"Masaaki","family":"Toyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2019.197677_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/jmbi.2000.4481","article-title":"Structural organization of the hepatitis B virus minichromosome","volume":"307","author":"Bock","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virusres.2019.197677_bib0010","doi-asserted-by":"crossref","first-page":"10262","DOI":"10.1128\/JVI.01360-08","article-title":"Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle","volume":"82","author":"Bourne","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2019.197677_bib0015","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1128\/JVI.00582-13","article-title":"Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids","volume":"87","author":"Campagna","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2019.197677_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2018.07.011","article-title":"Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro","volume":"158","author":"Corcuera","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2019.197677_bib0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.virusres.2019.197677_bib0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2019.197677_bib0035","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1099\/vir.0.18966-0","article-title":"Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore\/core proteins","volume":"84","author":"Fernandez","year":"2003","journal-title":"J Gen. Virol."},{"key":"10.1016\/j.virusres.2019.197677_bib0040","first-page":"117","article-title":"Mortality and Causes of Death Collaborators, 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"GBD","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2019.197677_bib0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis B therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virusres.2019.197677_bib0050","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1021\/ci700352q","article-title":"ASEDock-docking based on alpha spheres and excluded volumes","volume":"48","author":"Goto","year":"2008","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.virusres.2019.197677_bib0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2015.08.005","article-title":"Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapies","volume":"122","author":"Guo","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2019.197677_bib0060","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/epi.6.6.15815","article-title":"HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state","volume":"6","author":"Guo","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.virusres.2019.197677_bib0065","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X","article-title":"MMFF VI. MMFF94s option for energy minimization studies","volume":"20","author":"Halgren","year":"1999","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.virusres.2019.197677_bib0070","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T","article-title":"MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries","volume":"20","author":"Halgren","year":"1999","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.virusres.2019.197677_bib0075","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1128\/AAC.01711-12","article-title":"Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting cyclin T1\/Tat interaction","volume":"57","author":"Hamasaki","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virusres.2019.197677_bib0080","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/acsinfecdis.8b00081","article-title":"Virological Basis for the Cure of Chronic Hepatitis B","volume":"5","author":"Hu","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.virusres.2019.197677_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1515\/BC.2003.022","article-title":"Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells","volume":"384","author":"Kwon","year":"2003","journal-title":"Biol. Chem."},{"key":"10.1016\/j.virusres.2019.197677_bib0090","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/gut.51.4.597","article-title":"Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B","volume":"51","author":"Lim","year":"2002","journal-title":"Gut."},{"key":"10.1016\/j.virusres.2019.197677_bib0095","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1128\/JCM.00709-06","article-title":"A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA","volume":"45","author":"Liu","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.virusres.2019.197677_bib0100","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1128\/JVI.00394-16","article-title":"Cell-Free Hepatitis B Virus Capsid Assembly Dependent on the Core Protein C-Terminal Domain and Regulated by Phosphorylation","volume":"90","author":"Ludgate","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2019.197677_bib0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbrc.2014.08.029","article-title":"Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line","volume":"452","author":"Ogura","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.virusres.2019.197677_bib0110","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine."},{"key":"10.1016\/j.virusres.2019.197677_bib0115","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/S0960-894X(00)00544-8","article-title":"Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication","volume":"10","author":"Perni","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.virusres.2019.197677_bib0120","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","article-title":"Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones","volume":"130","author":"Pollicino","year":"2006","journal-title":"Gastroenterology."},{"key":"10.1016\/j.virusres.2019.197677_bib0125","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1039\/c2ob25195g","article-title":"Regioselective synthesis of pyrimido[1,2-a][1,3,5]triazin-6-ones via reaction of 1-(6-oxo-1,6-dihydropyrimidin-2-yl)guanidines with triethylorthoacetate: observation of an unexpected rearrangement","volume":"10","author":"Sachdeva","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.virusres.2019.197677_bib0130","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0409732102","article-title":"A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly","volume":"102","author":"Stray","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2019.197677_bib0135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly","volume":"19","author":"Stray","year":"2006","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.virusres.2019.197677_bib0140","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/hep.21345","article-title":"Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens","volume":"44","author":"Sugiyama","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2019.197677_bib0145","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1128\/JVI.03545-14","article-title":"The interface between HBV capsid proteins affects self-assembly,pgRNA packaging, and reverse transcription","volume":"89","author":"Tan","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2019.197677_bib0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(01)00216-9","article-title":"Inhibition of human hepatitis B virus (HBV) by a novel non- nucleosidic compound in a transgenic mouse model","volume":"54","author":"Weber","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.virusres.2019.197677_bib0155","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/ja00315a051","article-title":"A new force field for molecular mechanical simulation of nucleic acids and proteins","volume":"106","author":"Weiner","year":"1984","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.virusres.2019.197677_bib0160","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2019.197677_bib0165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","article-title":"The crystal structure of the human hepatitis B virus capsid","volume":"3","author":"Wynne","year":"1999","journal-title":"Mol. Cell."},{"key":"10.1016\/j.virusres.2019.197677_bib0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","article-title":"Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of HBV Infection","volume":"156","author":"Xia","year":"2019","journal-title":"Gastroenterology."},{"key":"10.1016\/j.virusres.2019.197677_bib0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.antiviral.2015.04.013","article-title":"The hepatitis B virus (HBV) core protein enhances the transcription activation of CRE via the CRE\/CREB\/CBP pathway","volume":"120","author":"Xiang","year":"2015","journal-title":"Antiviral Res."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170219304496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170219304496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:07:51Z","timestamp":1759154871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170219304496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":35,"alternative-id":["S0168170219304496"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2019.197677","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2019.197677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"197677"}}